Seferoğlu, MeralEthemoğlu, ÖzlemTuran, Ömer FarukSiva, Aksel2024-06-112024-06-112021-06-241590-1874https://doi.org/10.1007/s10072-021-05409-6https://link.springer.com/article/10.1007/s10072-021-05409-6https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223191/https://hdl.handle.net/11452/41954Background The use of disease-modifying therapies (DMTs) in people with multiple sclerosis (pwMS) may affect COVID-19 infection outcomes due to DMTs' immunomodulatory and immunosuppressive effects on immune response. The yet unknown issues are both the early response to the infection, as well as the post-infection development of immunity against the virus under these treatments due to their interaction with the immune system. Methods We report two asymptomatic cases of COVID-19 in patients with relapsing-remitting multiple sclerosis (RRMS) shortly after starting cladribine therapy, both developed anti-SARS-CoV-2 antibody response. Results Patients with MS who are under newly initiated treatment with cladribine tablets may experience an asymptomatic COVID-19 infection and they may develop immunity against SARS-CoV-2. Conclusion These observations raise the probability that DMTs with immunosuppressive effects, such as cladribine, may be considered as a treatment option for selected MS patients with high disease activity during the COVID-19 pandemic.eninfo:eu-repo/semantics/openAccessMultiple sclerosisCladribineCovid-19Sars-cov-2 antibody responseScience & technologyLife sciences & biomedicineClinical neurologyNeurosciencesNeurosciences & neurologyArticle0006656779000013533353542910.1007/s10072-021-05409-61590-3478